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EGFR Dinucleotide Repeat Polymorphism as a Prognostic
Indicator in Non-small Cell Lung Cancer
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Steven M. Keller, MD, Joan H. Schiller, MD,¶ David H. Johnson, MD,# and
Jill M. Kolesar, PharmD,§ for the Eastern Cooperative Oncology Group
Background: The epidermal growth factor receptor (EGFR) has been
implicated in tumor growth and progression. Intron 1 of the EGFR gene
contains a polymorphic simple sequence repeat (SSR) of 14 to 21 CA
dinucleotides, the length of which correlates inversely with the level of
EGFR transcription. The authors hypothesized that a shorter length of
tumor SSR would be associated with poorer survival in patients with
non-small cell lung cancer (NSCLC).
Methods: Patients enrolled in Eastern Cooperative Oncology Group
E3590 (a randomized, prospective trial of adjuvant therapy follow-
ing resection of stages II and IIIa NSCLC) were randomized to
radiation or radiation plus chemotherapy. Genomic DNA extracted
from resected tumors was amplified for EGFR intron 1 by polymer-
ase chain reaction and sequenced in a 3730XL DNA analyzer.
Results: One hundred fifty-seven primary tumors were sequenced,
106 (68%) of which were heterozygous for intron 1. The most
common genotypes were allele lengths of 17/19 dinucleotides
(17.8%), 17/18 (11.4%), and 19/19 (11.4%). Allele status (homozy-
gous versus heterozygous) did not correlate with race, gender,
weight, performance status, histology, stage, or survival. Shorter
allele length (18 versus 18 CA dinucleotide repeats) was asso-
ciated with squamous cell histology (p  0.03). Allele sum of
greater than 35 was associated with improved overall survival
(log-rank p  0.03, hazard ratio  0.66).
Conclusion: This is the first study to characterize the EGFR intron
1 SSR polymorphism in NSCLC. Tumors were most commonly
heterozygous for SSR length. Squamous histology was associated
with a shorter SSR. Longer sequences are associated with improved
survival.
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Lung cancer remains the leading cause of cancer-relateddeaths in the United States, with 160,000 new cases
estimated in the year 2006.1 Clinical parameters such as
stage, performance status, and weight loss reliably predict
survival. Although the mutational status of oncogene TP53
has not correlated with prognosis, KRAS mutation has been
associated with poor outcome in patients treated with epider-
mal growth factor receptor (EGFR) inhibitors.2,3
The signaling pathways triggered by EGFR activation
render the EGFR a logical correlate with tumor growth and
patient prognosis. Evidence for an important role of EGFR in
neoplasia includes its presence in premalignant bronchial
epithelium4,5 and decreased expression following regression
of metaplasia. EGFR overexpression in resected non-small
cell lung carcinoma (NSCLC) specimens has been associated
by some investigators with a worse prognosis.6 Others, how-
ever, found no statistically significant relationship, but did
note a trend toward worse prognosis with elevated EGFR or
increased EGFR gene copy.7 EGFR mutations have been
identified as a prognostic indicator with improved survival in
patients treated with chemotherapeutic agents.3
Transcription of the EGFR gene is regulated by two
enhancer elements. The first is located upstream near the
transcription initiation site and the second downstream in
intron 1.8 The latter contains a characteristic simple sequence
repeat (SSR) of CA dinucleotides, the length of which ex-
hibits interethnic differences.9 In addition, the length of this
polymorphism has been shown to correlate inversely with
EGFR transcription in both in vitro experiments and breast
cancer specimens.10,11 Eastern Cooperative Oncology Group
(ECOG) 3590 (a randomized, prospective trial of adjuvant
therapy following resection of stages II and IIIa NSCLC)
provided a unique opportunity to characterize the frequency
of EGFR polymorphisms in NSCLC specimens and deter-
mine whether the length of the SSR correlated with survival.
PATIENTS AND METHODS
Patient Population
ECOG 3590 was a multicenter, randomized, prospec-
tive trial designed to compare concurrent chemotherapy plus
radiation to radiation alone in the adjuvant treatment of
NSCLC.12 Patients with completely resected stages II and
IIIA were randomized to receive either thoracic radiation
(50.4 Gy) or thoracic radiation concurrent with chemother-
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apy. Chemotherapy consisted of four 28-day cycles of cis-
platin, 60 mg/m2 on day 1, and etoposide, 120 mg/m2 on days
1 to 3. Survival was similar in both study arms. Patients who
participated in ECOG 3590 and whose tumor tissue was
available for further analysis were eligible for enrollment in a
laboratory-based investigation (E4592).2 Institutional review
board approval of the laboratory study was obtained at each
institution. Informed consent was obtained from the patient or
surrogate.
Polymerase Chain Reaction
Genomic DNA extracted from resected tumors was
stored at –80°C. Intron 1 of the EGFR gene was amplified by
polymerase chain reaction (PCR) using primers purchased
from Integrated DNA Technologies, Inc. (Coralville, IA).
One microliter of DNA was mixed with 1 l of forward
primer, 5-GGA TGT CTC TTT TTG CTG TT, 1 l of
reverse primer 5-CTG TCA AGT GGG TTT ATG GT, 7 l
of nuclease-free water, and 10 l of Promega PCR Master
Mix (Promega Corporation, Madison, WI). Promega PCR
Master Mix contained Taq DNA polymerase in reaction
buffer with pH 8.5, nucleotides (dATP, dGTP, dCTP, dTTP),
and MgCl2. An MJ Research (PTC 100) thermocycler (Bio-
Rad Laboratories, Inc., Waltham, MA) was programmed to
cycle 55 times through the denaturation at 95°C, annealing at
50°C, and extension at 72°C, producing a 185 to 197 base
pair product, depending on the number of repeats.
The PCR product was purified with ExoSAP-IT (exo-
nuclease I and shrimp alkaline phosphatase in a specially
formulated buffer) from USB Corporation (Cleveland, OH),
as recommended by the manufacturer. Five microliters of
PCR product was mixed with 2 l of ExoSAP-IT and
incubated at 37°C for 15 minutes in a thermal cycler.
ExoSAP-IT was inactivated by heating to 80°C for 15 min-
utes.
Sequencing
The cleaned product was combined with the forward
PCR primer and sequenced at the University of Wisconsin
Biotechnology Center (Madison, WI). DNA PCR product
consisting of 20 ng and forward primer (5 pmol) were added
to the Enzyme Reaction Mix (2 l BigDye plus 3 l buffer
and 1 l of dimethyl sulfoxide) and water to 20 l. Cycling
conditions were as follows: 96°C for 3 minutes, then 35
cycles of 96°C for 10 seconds, 50°C for 15 seconds, 60°C for
3 minutes, finished with 72°C for 7 minutes.
Cleanup of sequenced product was performed with
CleanSeq beads as recommended by the manufacturer (Agen-
court Bioscience Corporation, Beverly, MA). Samples were
electrophoresed on an Applied Biosystems (Foster City, CA)
3730xl automated DNA sequencing instrument. Data were
analyzed using PE-Biosystems version 3.7 of Sequencing
Analysis. The resulting chromatograms were directly se-
quenced and scored by using computer software Chromas
version 2.3 (Griffith University, Queensland, Australia) (Fig-
ure 1). In our experience, the quality of the sequence is more
dependent on the location of the sequencing primer than on
the orientation (forward or reverse) of the primer. In this
assay, the primer was sufficiently downstream of the repeats
to provide accurate reads in the forward orientation. To
ensure accuracy, sequencing results were evaluated by two
independent observers and inconclusive results were re-
peated. Inconclusive results were caused by an inadequate
PCR amplification that resulted in a failed sequencing run.
Statistical Analysis
Tumor samples were analyzed for both allele status and
length. Intron 1 was classified as homozygous when the two
alleles had the same CA dinucleotide repeat number. In a
population-based case control study, the presence of two long
alleles of 19 or more was associated with an increased risk of
breast cancer.13 In a preclinical head and neck cancer study,
a difference in response to the EGFR tyrosine kinase inhibitor
erlotinib was seen when the sum of CA dinucleotides in both
alleles was dichotomized into 35 or 35.14 Because a
clinical difference was seen in different studies using differ-
ent cutoff values, both cutoff values were explored for our
analysis. The mean SSR length was calculated for each
patient and dichotomized as short (18) or long (18) based
on the number of dinucleotide repeats. Samples were also
divided into two cohorts based on the sum of their alleles: less
than or equal to 35 versus greater than 35. Recursive parti-
tioning and regression-tree techniques were used on the data
for each allele, with overall survival as the endpoint of
interest. This method attempts to mathematically divide the
data into appropriate homogeneous partitions (i.e., exploring
for a cutpoint or cutpoints). For alleles 1 and 2, no partitions
were found when the covariate was treated as a continuous
FIGURE 1. Intron 1 CA repeat
direct sequencing by Chromas
version 2.3.
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006 EGFR Polymorphism in Lung Cancer
Copyright © 2006 by the International Association for the Study of Lung Cancer 407
variable modeling survival using methods of Breiman et al. in
the statistical software R.15 When the sum of the alleles was
recursively partitioned, two homogeneous groups were found
(35.5 versus 35.5).
Descriptive statistics were used to describe patient
baseline characteristics. Using Fisher’s exact test at the 0.05
level, the association of both allele status and allele length
with patient characteristics was investigated.
Overall survival was defined as the time from random-
ization until death or date last known alive. Survival curves
were estimated by the method of Kaplan and Meier and
compared using log-rank tests. Cox proportional hazards
models were used to investigate the relationship between
survival and allele status after adjusting for various prognos-
tic factors. Similar models were also constructed for allele
length. Stepwise selection was used to choose parsimonious
models considering the following factors: gender (male ver-
sus female), age (60 versus 60 years), histology (squa-
mous versus other), weight loss in the previous 6 months
(5% versus5%), stage (II versus IIIa), performance status
(1 versus 0), and race (Caucasian versus other). All reported
TABLE 1. Correlation of Baseline Characteristics with Allele Status and Length
Baseline
Characteristics
E3590 Study
(%)
EGFR Dinucleotide Repeat Polymorphism Study (%)
Total
Homozygous
Alleles
Heterozygous
Alleles p Value <18 (CA)n >18 (CA)n pValue
Total 488 157
Age
 60
 60
243 (49.7)
245 (51.3)
85 (54.1)
72 (45.9)
28 (54.9)
23 (45.1)
57 (53.8)
49 (46.2)
0.9 47 (56.6)
36 (43.4)
38 (51.3)
36 (48.7)
0.52
Gender
Male
Female
285 (58.4)
203 (41.6)
95 (60.5)
62 (39.5)
26 (51.0)
25 (49.0)
69 (65.1)
37 (34.9)
0.12 51 (61.5)
32 (38.5)
44 (59.5)
30 (40.5)
0.87
Race
Caucasian
Other
418 (85.6)
70 (14.4)
138 (87.9)
19 (12.1)
46 (90.2)
5 (9.8)
92 (86.8)
14 (13.2)
0.61 77 (92.8)
6 (7.2)
61 (82.4)
13 (17.6)
0.05
ECOG PS
0
1
190 (38.9)
297 (60.8)
60 (38.2)
97 (60.8)
19 (37.2)
32 (62.8)
41 (38.7)
65 (61.3)
0.9 31 (37.3)
52 (62.7)
29 (39.2)
45 (60.8)
0.87
Weight loss in 6 mo
5%
5%
384 (78.6)
104 (21.3)
125 (79.6)
32 (20.4)
38 (74.5)
13 (25.5)
87 (82.1)
19 (17.9)
0.29 64 (77.1)
19 (22.9)
61 (82.4)
13 (17.6)
0.43
Stage
II
IIIa
202 (41.3)
285 (58.4)
75 (47.8)
82 (52.2)
25 (49.0)
26 (51)
50 (47.2)
56 (52.8)
0.87 39 (47)
44 (53)
36 (48.7)
38 (51.3)
0.87
Histology
Adenocarcinoma
Squamous
Other
259 (53.1)
170 (34.8)
59 (12.0)
83 (52.9)
53 (33.8)
21 (13.3)
27 (52.9)
17 (33.3)
7 (13.7)
56 (52.8)
36 (34.0)
14 (13.2)
0.9 40 (48.2)
35 (42.2)
8 (9.6)
43 (58.1)
18 (24.3)
13 (17.6)
0.04
ECOG PS, Eastern Cooperative Oncology Group Performance Status; 0, normal activity; 1, symptoms of disease but ambulatory; (CA)n ; CA dinucleotide repeat.
TABLE 2. Frequency of CA Dinucleotide Repeats in
Homozygous Samples
Homozygous (n  51)
(CA)n No. (%)
15 1 (0.6)
16 2 (1)
17 3 (2)
18 10 (6.3)
19 18 (11.4)
20 12 (8)
21 4 (2.5)
22 1 (0.6)
Percentages are calculated based on the total number (N157)
TABLE 3. Frequency of CA Dinucleotide Repeats in
Heterozygous Samples*
Heterozygous n  106
(CA)n No. (%) (CA)n No. (%)
11/13 1 (0.6) 17/20 4 (2.5)
13/15 1 (0.6) 18/19 4 (2.5)
15/16 1 (0.6) 18/20 4 (2.5)
15/17 3 (2) 19/20 9 (5.7)
16/17 9 (5.7) 19/21 1 (0.6)
16/18 4 (2.5) 20/21 2 (1)
16/19 2 (1) 20/22 9 (5.7)
17/18 18 (11.4) 21/22 3 (2)
17/19 28 (17.8) 21/23 3 (2)
*Percentages are calculated based on the total number (n  157).
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p values are associated with two-sided tests. Logistic regres-
sion models were used to assess the association between the
mean length of SSR with disease histology.
To assess for possible evolutionary changes occurring
in this allele polymorphism, Hardy-Weinberg analysis was
performed by matching allele frequencies in the observed
individuals to those expected under Hardy-Weinberg equilib-
rium (HWE). Genotypes were dichotomized as short or long
using three different cutoffs (17 versus 17), (18 versus
 18), and (19 versus 19), and compared using a 2
goodness-of-fit test.
RESULTS
Four hundred eighty-eight patients were enrolled in the
E3590 trial. One hundred fifty-seven primary tumor samples
were available for EGFR intron 1 analysis. The demographic
distribution of these patients was similar to the patients on the
ECOG 3590 trial (Table 1). The lengths of the two alleles
were heterozygous in 106 samples (68%). The most common
genotypes contained allele lengths of 17/19 dinucleotides
(17.8%), 17/18 (11.4%), and 19/19 (11.4%) (Tables 2 and 3).
Hardy-Weinberg Equilibrium Analysis
Allele frequencies were dichotomized as short or long
using three different cutoffs (17 versus17,18 versus
18, and 19 versus 19). For all cutoffs used, the alleles
were not in HWE (17 versus 17, p 0.0001;18 versus
 18, p  0.034; and 19 versus 19, p  0.034). The
observed frequency of the heterozygous pair (short/long) was
less than expected, whereas the observed frequencies of the
homozygous pairs (short/short) and (long/long) were greater
than expected. When analyzed by race, alleles were not in
HWE in Caucasians for each of the cutoffs (p  0.001, p 
0.03, and p  0.001, respectively). In African Americans,
alleles were in HWE for cutoffs less than 18 versus greater
than or equal to 18 (p  0.46) and less than 19 versus greater
than or equal to 19 (p  0.46) However, once again, the
frequencies of the heterozygous pairs were fewer than ex-
pected and the frequencies of homozygous pairs exceeded the
expected frequency.
Analysis of Allele Status
Allele status (homozygous versus heterozygous) was
not significantly associated with baseline characteristics such
as race, gender, weight loss in previous 6 months, perfor-
mance status, histology (squamous versus other, p  0.9;
adenocarcinoma versus other, p  0.9), and stage (Table 1).
In addition, there was no significant difference in median
survival between homozygous and heterozygous patients
(50.7 months versus 38.5 months, p  0.40) (Table 4 and
Figure 2). In multivariate analyses, allele status was not
associated with survival.
Analysis of SSR Length
Seventy-four of the 157 tumor samples (47%) were
categorized as having long (18) allele length (Table 1). A
logistic regression model with length as the outcome and
histology (squamous, other, and adenocarcinoma) was con-
ducted. There was a significant association between SSR
length and histology (p  0.047). Patients with squamous
histology had approximately two times the odds of a shorter
SSR length in comparison with patients with adenocarcinoma
histology (odds ratio, 2.1; 95% confidence interval [CI],
1.02–4.27; p 0.01). Patients with other histology had lower
odds of shorter SSR length in comparison with patients with
squamous cell histology, although these two groups were not
statistically different from each other (odds ratio, 0.66; 95%
CI, 0.25–1.76; p 0.11). Caucasian race was associated with
a shorter SSR length than other races (p  0.05). SSR
average length was not significantly associated with gender,
weight loss, stage, or performance status.
The median survival of the 488 patients treated on
clinical trial E3590 was 39 months (95% CI, 30–52 months).
The median survivals of those who were randomized to
TABLE 4. Correlation of Median Survival with Allele Status
and Length
No. of Patients
(%)
Median survival
(mo)
Allele status
Homozygous
Heterozygous
51 (32)
106 (68)
50.7 (p  0.40)
38.5
Sum of alleles (CA)n
35
35
45 (28.6)
112 (71.3)
29.2 (p  0.03)
41
(CA)n , CA dinucleotide repeats.
FIGURE 2. Survival did not correlate with allele status.
There was no statistically significant difference between the
median survival of homozygous (50.7 months) and het-
erozygous (38.5 months) alleles (p  0.40).
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006 EGFR Polymorphism in Lung Cancer
Copyright © 2006 by the International Association for the Study of Lung Cancer 409
postoperative radiation and postoperative chemoradiation
were 39 and 38 months, respectively (p  0.56). Of the 157
patients who were analyzed for intron 1 polymorphism, using
multivariate analysis with Cox proportional hazards, when
analyzed by the sum of the alleles, a significant difference
was found in favor of the longer allele. Patients with an allele
sum of less than or equal to 35 had a median overall survival
of 29.2 months (95% CI, 21.3–51.4 months), whereas pa-
tients with an allele sum of greater than 35 had a median
overall survival of 41.0 months (95% CI, 35.8–66.3) (hazard
ratio [HR], 0.66; p  0.03) (Figure 3 and Table 4). When
controlling for treatment randomization in this study, the
difference in overall survival is still statistically significant
between the two allele groups (2 p  0.03; HR, 0.655), with
the longer allele being associated with higher survival (Table
5). Exploratory analyses using recursive partitioning was
conducted on the allele length averages. Two homogeneous
groups were found (18 versus 18) whose survivals were
identical to homogeneous groups of the sum of the allele
lengths (35 versus 35).
DISCUSSION
The cell surface receptor family is representative of the
receptor tyrosine kinases and consists of four subfamilies.
The most extensively studied of the subfamilies have been
EGFR (ERBB1) and Her2-neu (ERBB2). Both molecules are
expressed in normal and neoplastic tissue. On ligand activa-
tion of the extracellular domain, homodimerization between
similar subfamilies or heterodimerization between different
subfamilies occurs. This results in phosphorylation of the
intracellular tyrosine kinase domain, which in turn triggers
downstream pathways including mitogen-activated protein
kinase, phosphatidyl inositol-3 kinase, and Akt.16 These pro-
cesses, which then regulate several transcription factors in-
volved in cell growth, migration, adhesion, and apoptosis,
contribute to the mitogenic potentials of cells and thus tumor
growth. Because EGFR-dependent growth increases follow-
ing neoplastic transformation,17 the level of EGFR expression
would be expected to correlate with survival.
Indeed, breast tumors expressing Her2-neu were asso-
ciated with shorter survival.18 In addition, the level of Her2-
neu expression correlated with response to anti–Her2-neu
treatment.19 However, in patients with NSCLC, tumor EGFR
protein expression does not reproducibly correlate with sur-
vival or treatment response to EGFR inhibitors.7,20 Theoret-
ical but as yet unproven explanations for the lack of correla-
tion include the ability of tumor cells to bypass the EGFR
pathway and use alternate pathways for cell cycle progres-
sion. It is also possible that the presence of EGFR mutations
may alter the response to EGFR inhibitors, negating the
importance of EGFR expression.21,22 ERBB2 heterodimers
are more potent than homodimers and lead to increased and
prolonged downstream signaling.16 Thus, coexpression of
ERBB1 and ERBB2 may be more important than the expres-
sion of EGFR alone.
The EGFR gene is located on chromosome 7 and
contains 26 exons.23 Exons 1 to 14 code for the extracellular
domain, exon 15 codes for the transmembrane domain, and
exons 16 to 26 code for the intracellular domain. Two
enhancer elements, one upstream near the transcription initi-
ation site and the other downstream in intron 1, regulate
transcription.8 The first intron contains a characteristic SSR
of repeating (CA) dinucleotides. A polymorphism of 14 to 21
CA dinucleotides is present at a heterozygosity of 72% of
Caucasians.24 A longer sequence of 20 CA repeats is associ-
ated with Asian ethnic heritage and a shorter sequence of 16
repeats is associated with Caucasian and African American
heritage.9
Allele length in breast cancers is inversely proportional
to the level of EGFR transcription.11 Transcription decreased
FIGURE 3. Survival correlated with the number of dinucle-
otide repeats when dichotomized by mean sum of alleles.
Allele sum of less than or equal to 35 had a median overall
survival of 29.2 months (95% CI, 21.3–51.4 months),
whereas patients with an allele sum greater than 35 had a
median overall survival of 41.0 months (95% CI, 35.8–66.3
months; HR, 0.66; p  0.03).
TABLE 5. Survival by Treatment Groups
No.
(CA)n
Sum of
Both Alleles Treatment
Median
OS (mo) 95% CI
23 35 RT 38.2 21.0–52.7
56 35 RT 41.5 32.5–92.9
22 35 Chemotherapy
and RT
25.3 16.0–75.2
56 35 Chemotherapy
and RT
40.9 30.8–75.0
(CA)n, CA dinucleotide repeats; RT, radiation therapy.
S. Dubey et al. Journal of Thoracic Oncology • Volume 1, Number 5, June 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer410
by approximately 80% when there were 21 repeats, resulting
in decreased cellular EGFR protein levels.10 In NSCLC,
squamous cell histology is associated with higher EGFR
content,7 and thus this subtype would be expected to have
shorter allele lengths. This was supported by the findings in
our study that demonstrated that shorter allele lengths are
strongly associated with squamous histology.
The predominant SSR genotype in normal controls,
colon cancers, and breast cancers is heterozygous allele
lengths of 16/20 repeats.11,13,24,25 Although the most common
genotype in our NSCLC samples was similarly heterozygous,
the most common allele lengths were 17/19. The presence of
two alleles containing 19 CA repeats (which occurred in
10% of tumors) conferred an increased risk of breast cancer
development in women with a family history of breast cancer
when compared with shorter alleles.13 In our study, the
frequency of two long alleles (19 CA) was 39.5%. Because
the genotype that confers an increased risk of malignancy in
breast cancer occurs even more commonly in the tumors of
patients with NCSLC, it raises the question of whether
increased lengths of this repeat sequence increase the risk of
lung cancer development.
The Hardy-Weinberg formula measures gene frequen-
cies in a reference population. Comparing gene frequencies in
a disease-carrying population, such as NSCLC, as was done
in the current study, to the reference population is one way of
assessing the importance of that gene on the particular dis-
ease. The HWE will be maintained if random mating occurs
in a large population, there is no migration in or out of the
population, and neither mutation nor natural selection occurs.
In our study, we found that the alleles were not in HWE.
Because ECOG 3590 was a national multicenter trial, it is
reasonable to assume that the population involved was large
and diverse and that mating was random. Gene mutation is
also an unlikely explanation for the lack of HWE, as the SSR
polymorphism has been described in both normal controls
and in the malignant population. Therefore, natural selection
remains the most likely cause of the deviation from HWE. An
increase in the frequency of homozygous pairs was seen in
our study, suggesting that EGFR homozygous long pairs and
short pairs, but not the heterozygous pairs, are important in
the development of NSCLC and may confer a survival
advantage on the developing neoplasm. In the subset of
African Americans patients, the genes were found to be in
HWE, suggesting that natural selection of the SSR polymor-
phism did not occur. However, because the sample size of
African Americans in our study was small, these results
should be interpreted with caution. Analysis of the MDR
(multiple drug resistance) gene polymorphism in tumor sam-
ples of the same population demonstrated alleles to be in
HWE (J. Kolesar et al., unpublished data, 2004). This sug-
gests that loss of HWE did not occur for all genes evaluated
in NSCLC tumors but was specific for the EGFR gene,
supporting the role of EGFR in the development of cancer.
The sum of the CA repeats of both alleles greater than
35 was associated with improved survival. This difference
was maintained when patients were randomized by treatment
group. A similar cutoff was seen in the preclinical head and
neck cancer study, where cell lines with a sum of CA repeats
greater than 35 were associated with resistance to erlotinib,
suggesting that the polymorphism may be a predictor of
response to EGFR inhibitors.14 In this preclinical study, as
seen with other studies, an increase in the length of the
polymorphic sequence was associated with decreasing EGFR
protein levels. Gene amplification was not seen in these cell
lines, eliminating the role of gene amplification in EGFR
overexpression, suggesting that EGFR intron 1 polymor-
phism may play an important role in influencing response to
EGFR inhibitors indirectly by regulating transcription of
EGFR. Thus, we cannot exclude the possibility that the
prognostic ability of the intron 1 polymorphism seen in our
study may be related to EGFR levels. Because of tumor
sample limitations, EGFR protein levels were not evaluated
in our study and should be addressed in a future study. A
multivariate analysis in such a study may ascertain the prog-
nostic value of the intron 1 polymorphism, independent of
EGFR expression. Because polymorphisms are not unique to
tumor tissue, nonmalignant tissue may have sufficed to study
this polymorphism as an independent marker. In addition,
nonmalignant tissue may have provided a reference for com-
parison with tumor tissue to assess for potential changes
during the malignant process, but the absence of banked
matched blood samples did not permit this step. However, our
study enabled a unique opportunity to evaluate a biomarker
such as the intron 1 polymorphism in tumor tissue in a large
cooperative group study with available survival data.
CONCLUSIONS
Distribution of the EGFR gene intron 1 polymorphism
in stages II and IIIa NSCLC differs from that reported in
noncancerous populations and other malignancies. The poly-
morphism correlates with histology and with prognosis. Fur-
ther study is needed to detect other potential effects of this
sequence. The correlation of intron 1 polymorphism with
response to treatment with EGFR inhibitors should be eval-
uated in future clinical trials. Further study to evaluate loss of
heterozygosity in tumor in comparison with reference non-
malignant tissue should be undertaken. The impact of inter-
actions between intron 1 polymorphism and risk factors such
as family history and smoking on lung cancer development
warrant an exploration.
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